Geneseeq Canada Named First Genomic Testing Partner in UHN's SHERLOCK Study, a 7,000-Patient Prospective Cancer Genomics Platform
核心洞察
Geneseeq Canada becomes the first commercial genomic testing partner for UHN's SHERLOCK study, a large-scale prospective cancer research platform at Princess Margaret Cancer Centre.
The SHERLOCK study aims to enroll approximately 7,000 patients over five years across multiple solid tumors and hematologic malignancies to evaluate genomic technologies in cancer care.
Geneseeq will provide genomic profiling and molecular residual disease monitoring services for approximately 1,000 participants using its GeneseeqPrime® (搜索), Shielding® Ultra (搜索), and Hemasalus® (搜索) assays.
Geneseeq Technology Inc. (搜索) (Geneseeq Canada) has been named the first commercial genomic testing partner in University Health Network's SHERLOCK study, a large-scale prospective cancer research platform at the Princess Margaret Cancer Centre in Toronto. Announced on July 14, 2026, the collaboration positions Geneseeq Canada to provide genomic testing, molecular residual disease (MRD) monitoring capabilities, and support for precision oncology translational research across Canada.
The SHERLOCK study (ClinicalTrials.gov NCT07524114) is expected to enroll approximately 7,000 patients over five years, spanning multiple solid tumors and hematologic malignancies. By following patients longitudinally and analyzing both tumor tissue and blood samples, the study aims to better understand treatment response, disease recurrence, and cancer evolution, while evaluating how genomic technologies may help inform future cancer care.
Genomic Technologies Deployed
For selected participants enrolled in the SHERLOCK program, Geneseeq technologies may be used for specific genomic profiling and molecular monitoring activities, depending on study needs and sample availability. For participants with solid tumors, baseline tumor tissue samples may be analyzed using GeneseeqPrime® (搜索), the company's comprehensive genomic profiling assay, to characterize the molecular features of their cancers. Longitudinal blood samples may be analyzed using Shielding® Ultra (搜索), Geneseeq's molecular monitoring technology designed to track cancer-related signals with high sensitivity over time using either matched tumor tissue information or blood samples alone. For participants with hematologic malignancies, genomic analyses may be performed using Hemasalus® (搜索), Geneseeq's comprehensive genomic profiling assay for blood cancers.
Geneseeq Canada is providing genomic testing and molecular monitoring services for approximately 1,000 patients participating in the study.
Leadership Perspectives
"Canada has played an important role in Geneseeq's journey," said Dr. Xue Wu, CEO of Geneseeq Canada. "We are pleased to support Canadian-led cancer research through the SHERLOCK program and honoured to become its first commercial genomic testing partner. Our participation reflects Geneseeq's long-term commitment to advancing the scientific understanding of cancer genomics and MRD while supporting research that may ultimately benefit patients."
Dr. Lillian Siu, Clinician and Senior Scientist at UHN's Princess Margaret Cancer Centre, emphasized the clinical imperative driving the research. "Advancing precision oncology requires close collaboration between academic institutions, healthcare systems, and industry partners," said Dr. Siu. "One of the biggest challenges in cancer care is knowing whether curative treatment has truly eliminated cancer or whether the disease remains and may return. Through SHERLOCK, we are following patients over time and combining genomic analyses with clinical outcomes to better understand treatment response, detect signs of recurrence earlier, and generate evidence that could help guide future approaches to cancer monitoring and care."
Broader Implications
SHERLOCK is expected to generate important evidence regarding the biological and clinical significance of molecular residual disease and may help inform future precision oncology strategies, clinical trial design, and biomarker research. The study is one of several ongoing collaborative efforts between Geneseeq and UHN investigators aimed at advancing cancer genomics, early detection, molecular residual disease research, and precision oncology.
Geneseeq Technology Inc. (搜索), headquartered in Ontario, Canada, operates CAP- and CLIA-certified laboratories and provides access to an integrated portfolio spanning comprehensive genomic profiling across tumor types, MRD monitoring, and multi-cancer early detection solutions. Its flagship assay, GeneseeqPrime® (搜索), is FDA-cleared in the United States, CE-IVD marked in Europe, and NMPA-approved in China. The company's Shielding® Ultra (搜索) MRD assay and Hemasalus® (搜索) hematological malignancy genomic profiling assay are also CE-IVD marked.